|
KLRC4-KLRK1
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The NKG2D-NKG2D ligand (NKG2DL) pathway has been considered to be promising target for immunotherapy because of the selective expression of "stress-induced ligands" on tumor cells and the strong NK cell activating potency of NKG2D.
|
31720075 |
2019 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
CAR T cells based on modified NKG2D receptors are effective against many types of tumors, and their efficacy is mediated through direct cytotoxicity and cytokine production.
|
27849169 |
2016 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
We observe the downregulation of several activation receptors including CD16, CD62L, C-X-C chemokine receptor (CXCR)-4, natural killer group 2 member D (NKG2D), DNAX accessory molecule (DNAM)-1, and NKp46 following tumor-priming.
|
31242243 |
2019 |
|
KLRC4-KLRK1
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The strong expression of NKG2D ligands by tumor cells was confirmed in situ by immunohistochemical staining of KS biopsies.
|
22253598 |
2012 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
Notably, NK cell clones expressing low surface densities of NCR (NCR(dull)) could lyse these tumors in an exclusively NKG2D-dependent fashion.
|
11298332 |
2001 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
Studies using RNA interference not only revealed a prominent role of ADAM10 and ADAM17 in NKG2D ligand shedding but also a tumor cell-specific role of ADAM10 and/or ADAM17 in shedding of MICA or MICB.
|
23526433 |
2013 |
|
KLRC4-KLRK1
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Whereas MICA expressed on the cell surface stimulates the immunoreceptor natural killer group 2, member D (NKG2D), the secreted form down-regulates NKG2D activity, thus allowing the tumor to escape immunosurveillance by NKG2D-expressing cells.
|
18951065 |
2009 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
Murine NKG2D recognition of MICA/B is an important receptor-ligand interaction used by NK cells in immunodeficient strains to limit engraftment of human tumors.
|
19447870 |
2009 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
The stimulatory NKG2D receptor on lymphocytes promotes tumor immune surveillance by targeting ligands selectively induced on cancer cells.
|
25291178 |
2014 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
In a form of autoimmune attack, NKG2D promotes tissue damage, mostly in the inflamed tissue adjacent to the tumor, facilitating tumor progression while being ineffective at rejecting transformed cells in the tumor bed.
|
30150983 |
2018 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
In a co-culture system of tumour cell culture supernatant (TSN) and murine NK cell, IDO1 was substantially increased, while NKG2D was markedly downregulated in NK cells.
|
30268986 |
2018 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
Notably, antagonizing miR-20a action enhanced the NKG2D-mediated killing of tumor cells in both in vitro and in vivo models of tumors.
|
24813230 |
2014 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
Ultimately prescreening patients undergoing such immune cell therapies might be used to personalize cancer treatment regimens based on the NKG2D-ligand status of the tumor.
|
21389869 |
2011 |
|
KLRC4-KLRK1
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Thus, it is essential to regulate the expression of NKG2D ligands in order to ensure effective tumor immunosurveillance and the elimination of pathogen-infected cells.
|
18422748 |
2008 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
However, soluble NKG2D ligands are released from tumour cells and can down-modulate NKG2D activation as a means of tumour immune escape.
|
23679194 |
2013 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, our result suggests that the inhibition of cleavage and release of MIC molecules from the tumor surface could potentially improve NKG2D-dependent cytotoxicity.
|
26449615 |
2017 |
|
KLRC4-KLRK1
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Here, the expression of NKG2D ligands was investigated in human primary NB tumors and cell lines because scanty information is available on this issue.
|
15548365 |
2005 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, is reported to exert anti-tumor effects by upregulating the expression of the natural killer group 2D (NKG2D) ligands on tumor cells; however, the mechanisms vary in different tumor types, and the effect and mechanism of action of VPA in pancreatic cancer cells are unknown.
|
24885711 |
2014 |
|
KLRC4-KLRK1
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Upon coculture with LN MSCs, CD8(+)αβT and γδT cells strongly reduced their cytolytic activity against NKG2D-L(+) targets; this seems to be the result of TGF-β, present at the tumor site, produced in vitro by LN MSCs and able to down-regulate the expression of NKG2D on T lymphocytes.
|
22167753 |
2012 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, our data provide strong evidence for an immune escape mechanism of tumors via alternative splicing of ULBP RNA to generate a free soluble ULBP protein, RAET1E2, that may impair NKG2D-mediated NK cell cytotoxicity to tumors.
|
17470428 |
2007 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, our data suggest that ULBP4 functions as a ligand for both TCRgammadelta and NKG2D and may play a key role in immune surveillance of tumor development and clearance of viral infection.
|
19436053 |
2009 |
|
KLRC4-KLRK1
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Consistent with these signaling activities, above-threshold expression of NKG2D-DAP10 in a ligand-bearing tumor line increases its bioenergetic metabolism and proliferation, thus suggesting functional similarity between this immunoreceptor and tumor growth factor receptors.
|
21321202 |
2011 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
All of these features affect the characteristics of the immune response exerted by NKG2D-expressing cells and are likely to be important factors in the clearance of a tumour or the development of autoimmunity.
|
29521021 |
2018 |
|
KLRC4-KLRK1
|
0.100 |
AlteredExpression
|
group |
BEFREE |
<b>Purpose:</b> NKG2D ligands (NKG2DL) are expressed on various tumor types and immunosuppressive cells within tumor microenvironments, providing suitable targets for cancer therapy.
|
28659311 |
2017 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
Proteolytic shedding of ligands for the NK group 2D (NKG2D) receptor is a strategy used by tumors to modulate immune recognition by NK cells and cytotoxic T cells.
|
24973455 |
2014 |